Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis
Primary Purpose
ACUTE RESPIRATORY DISTRESS SYNDROME
Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
extracorporeal removal of CO2 (ECCO2-R)
No extracorporeal CO2-removal
Sponsored by
About this trial
This is an interventional treatment trial for ACUTE RESPIRATORY DISTRESS SYNDROME
Eligibility Criteria
Inclusion criteria:
- Acute onset of ARDS criteria on chest X-ray or CT scan
- Moderate (PaO2/ FiO2 <200) or severe ARDS (PaO2/ FiO2 <100) (FiO2: fraction of inspired oxygen)
- Respiratory acidosis with pH< 7,25,
- With plateau pressure of 28cmH20 or higher,
Exclusion criteria:
- <18 years of age
- Pregnancy
- Obesity with BMI> 30
- Contraindication for anticlotting therapy
- Chest wall abnormalities
- No presumed consent of representatives
Sites / Locations
- Ghent University Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
extracorporeal CO2
Arm Description
Outcomes
Primary Outcome Measures
To obtain a reduction of 20% in arterial partial CO2 pressure (PaCO2) after the first two hours of ECCO2-R therapy.
Arterial blood gasses, ventilator settings will be measured.
Secondary Outcome Measures
Reduction in Plateau pressures to levels between 25 and 28 cm H2O.
Arterial blood gasses and ventilator settings will be measured.
• Reduction in tidal volumes to 6ml/kg predicted body weight (PBW) or lower, with a minimum of 3ml/kg PBW.
Arterial blood gasses and ventilator settings will be measured.
Increase in pH to the normal range of 7,35 to 7,45.
Arterial blood gasses and ventilator settings will be measured.
Full Information
NCT ID
NCT01911533
First Posted
July 23, 2013
Last Updated
December 12, 2022
Sponsor
University Hospital, Ghent
1. Study Identification
Unique Protocol Identification Number
NCT01911533
Brief Title
Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis
Official Title
Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis.
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
February 20, 2014 (Actual)
Primary Completion Date
June 12, 2014 (Actual)
Study Completion Date
September 12, 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Ghent
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hypothesis:
Extracorporeal removal of CO2 can treat hypercapnia and respiratory acidosis, which allows application of lung protective ventilation. This downgrading of mechanical ventilation promotes better and more quickly lung recovery.
Aim:
The aim of the study is to treat respiratory acidosis and to reduce plateau pressures by using an extracorporeal removal of CO2 (ECCO2-R).
This prospective study will include 10 patients with an Acute Respiratory Distress Syndrome (ARDS). ARDS is an inflammatory response in the lungs, the onset is acute with pulmonary oedema and shows bilateral densities on chest radiography. The take up of oxygen and the loss of CO2 in the lungs are difficult. Moreover the patient's blood can become acidic due to too much CO2.
To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
The investigators will use a standard dialysis catheter that will be put in a large vein. To prevent clotting of the system, the patient will receive heparin.
In the study the investigators will work in periods of two hours, the situation before and after carbon dioxide removal will be compared. With this study the investigators want to prove that the CO2 in the blood decreases with at least 20 % with the use of the extracorporeal CO2 remover. More over the investigators want to prove that lower mechanical ventilation settings (thanks to CO2-removal by the ECCO2-R) will produce fewer lesions to the lungs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ACUTE RESPIRATORY DISTRESS SYNDROME
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
extracorporeal CO2
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
extracorporeal removal of CO2 (ECCO2-R)
Intervention Description
To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
Intervention Type
Procedure
Intervention Name(s)
No extracorporeal CO2-removal
Intervention Description
Patients are their own control group.
Primary Outcome Measure Information:
Title
To obtain a reduction of 20% in arterial partial CO2 pressure (PaCO2) after the first two hours of ECCO2-R therapy.
Description
Arterial blood gasses, ventilator settings will be measured.
Time Frame
After the first two hours of ECCO2-R therapy, every 2 hours for a maximum of 5 days.
Secondary Outcome Measure Information:
Title
Reduction in Plateau pressures to levels between 25 and 28 cm H2O.
Description
Arterial blood gasses and ventilator settings will be measured.
Time Frame
Every 2 hours during procedure for a maximum of 5 days.
Title
• Reduction in tidal volumes to 6ml/kg predicted body weight (PBW) or lower, with a minimum of 3ml/kg PBW.
Description
Arterial blood gasses and ventilator settings will be measured.
Time Frame
Every 2 hours during the procedure for a maximum of 5 days.
Title
Increase in pH to the normal range of 7,35 to 7,45.
Description
Arterial blood gasses and ventilator settings will be measured.
Time Frame
Every 2 hours during the procedure for a maximum of 5 days.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Acute onset of ARDS criteria on chest X-ray or CT scan
Moderate (PaO2/ FiO2 <200) or severe ARDS (PaO2/ FiO2 <100) (FiO2: fraction of inspired oxygen)
Respiratory acidosis with pH< 7,25,
With plateau pressure of 28cmH20 or higher,
Exclusion criteria:
<18 years of age
Pregnancy
Obesity with BMI> 30
Contraindication for anticlotting therapy
Chest wall abnormalities
No presumed consent of representatives
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Harlinde Peperstraete, MD
Organizational Affiliation
University Hospital, Ghent
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ghent University Hospital
City
Ghent
ZIP/Postal Code
9000
Country
Belgium
12. IPD Sharing Statement
Citations:
PubMed Identifier
29179681
Citation
Peperstraete H, Eloot S, Depuydt P, De Somer F, Roosens C, Hoste E. Low flow extracorporeal CO2 removal in ARDS patients: a prospective short-term crossover pilot study. BMC Anesthesiol. 2017 Nov 28;17(1):155. doi: 10.1186/s12871-017-0445-9.
Results Reference
derived
Links:
URL
http://www.uzgent.be
Description
Related Info
Learn more about this trial
Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis
We'll reach out to this number within 24 hrs